Biogen reported a solid start to the year with its Q1 2026 results, featuring 12% growth in new products and a major move to acquire Apellis Pharmaceuticals to bolster its rare disease and nephrology portfolios.
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
Novo Nordisk will present 52 abstracts at the European Congress on Obesity, showcasing a portfolio that includes high-dose Wegovy and new data on women’s health during menopause.
AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
Gilead Sciences has finalized its $7.8 billion acquisition of Arcellx, Inc., positioning the company for the potential 2026 commercial launch of the BCMA-directed CAR T-cell therapy, anito-cel.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Eli Lilly and Company expands its oncology portfolio through the Lilly Ajax Therapeutics acquisition, targeting breakthroughs in myeloproliferative neoplasms with AJ1-11095.
Sun Pharmaceutical Industries has announced a definitive agreement to acquire Organon & Co. for $11.75 billion, marking a major expansion into women’s health and biosimilars.
The Foundayo launch impact on Eli Lilly has been swift and sharp — while FDA approval of orforglipron marked a historic first for oral GLP-1 obesity treatment, early prescription data trailing Novo Nordisk’s Wegovy sent LLY stock down as much as 4.3%, forcing analysts to slash 2026 revenue forecasts from $5 billion to just $1.3–1.6 billion.
Johnson & Johnson Atraverse Medical’s acquisition marks a significant milestone in the field of electrophysiology. Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to [Read More…]
